MX421834B - Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia - Google Patents
Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demenciaInfo
- Publication number
- MX421834B MX421834B MX2020008345A MX2020008345A MX421834B MX 421834 B MX421834 B MX 421834B MX 2020008345 A MX2020008345 A MX 2020008345A MX 2020008345 A MX2020008345 A MX 2020008345A MX 421834 B MX421834 B MX 421834B
- Authority
- MX
- Mexico
- Prior art keywords
- dementia
- adrenomedullin
- therapy
- adm
- prediction
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155682 | 2018-02-08 | ||
| PCT/EP2019/052982 WO2019154900A1 (en) | 2018-02-08 | 2019-02-07 | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020008345A MX2020008345A (es) | 2020-09-25 |
| MX421834B true MX421834B (es) | 2025-03-14 |
Family
ID=61188647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008345A MX421834B (es) | 2018-02-08 | 2019-02-07 | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210302440A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3749959A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021513077A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102717599B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN119770645A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019219071A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020014940A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090736A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276564A (cg-RX-API-DMAC7.html) |
| MX (1) | MX421834B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202006686SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019154900A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4110372A1 (en) * | 2020-02-26 | 2023-01-04 | PAM Theragnostics GmbH | Use of peptidylglycine alpha-amidating monooxygenase (pam) for therapeutic purpose |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| JP2023515981A (ja) | 2020-02-26 | 2023-04-17 | ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ペプチジルグリシンαアミド化モノオキシゲナーゼ(PAM)を決定する方法および診断目的でのその使用 |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| EP4680966A1 (en) | 2023-03-17 | 2026-01-21 | PAM Theragnostics GmbH | Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose |
| WO2025133203A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
| WO2025133225A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam) |
| WO2026099249A1 (en) | 2024-11-05 | 2026-05-15 | Pam Theragnostics Gmbh | Modified and unmodified peptidylglycine alpha-amidating monooxygenase (pam) for use in subjects having increased amyloid-beta and/or phospho-tau-protein load and/or neuroinflammation |
| WO2026099243A1 (en) | 2024-11-05 | 2026-05-15 | Pam Theragnostics Gmbh | Modified and unmodified peptidyl-glycine alpha-amidating monooxygenase (pam) for use in the treatment or prevention of cerebral hypoperfusion for the improvement of cerebral blood flow (cbf) |
| WO2026132535A1 (en) | 2024-12-20 | 2026-06-25 | B.R.A.H.M.S Gmbh | Pro-adrenomedullin and fragment(s) thereof for diagnosis and/or prognosis of a central nervous system inflammation |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DE102005036094A1 (de) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen |
| US20090306227A1 (en) | 2005-08-31 | 2009-12-10 | Toshiyuki Ioka | Tablet for removing tongue coating |
| DE102006027818A1 (de) * | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| WO2009095454A2 (de) * | 2008-02-01 | 2009-08-06 | Brahms Aktiengesellschaft | Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| BR112012014417B1 (pt) | 2009-12-14 | 2021-11-09 | Scil Proteins Gmbh | Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| FR2964103B1 (fr) * | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| BR112014011670B1 (pt) * | 2011-11-16 | 2021-05-25 | Adrenomed Ag | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica |
| US9140696B2 (en) | 2011-11-16 | 2015-09-22 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| US20160230227A1 (en) * | 2012-12-21 | 2016-08-11 | The New York Stem Cell Foundation | Methods of treating alzheimer's disease |
| CN109716136B (zh) * | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
-
2019
- 2019-02-07 KR KR1020207025729A patent/KR102717599B1/ko active Active
- 2019-02-07 AU AU2019219071A patent/AU2019219071A1/en not_active Abandoned
- 2019-02-07 JP JP2020542645A patent/JP2021513077A/ja active Pending
- 2019-02-07 US US16/968,483 patent/US20210302440A1/en active Pending
- 2019-02-07 CA CA3090736A patent/CA3090736A1/en active Pending
- 2019-02-07 BR BR112020014940-3A patent/BR112020014940A2/pt not_active IP Right Cessation
- 2019-02-07 CN CN202411684173.XA patent/CN119770645A/zh active Pending
- 2019-02-07 EP EP19702467.2A patent/EP3749959A1/en active Pending
- 2019-02-07 CN CN201980012542.1A patent/CN111902721B/zh active Active
- 2019-02-07 MX MX2020008345A patent/MX421834B/es unknown
- 2019-02-07 SG SG11202006686SA patent/SG11202006686SA/en unknown
- 2019-02-07 WO PCT/EP2019/052982 patent/WO2019154900A1/en not_active Ceased
-
2020
- 2020-08-06 IL IL276564A patent/IL276564A/en unknown
-
2022
- 2022-12-30 US US18/148,633 patent/US20230221339A1/en active Pending
-
2023
- 2023-10-06 JP JP2023174585A patent/JP2024001208A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102717599B1 (ko) | 2024-10-14 |
| CN111902721B (zh) | 2024-12-13 |
| IL276564A (en) | 2020-09-30 |
| CN119770645A (zh) | 2025-04-08 |
| CA3090736A1 (en) | 2019-08-15 |
| KR20200135947A (ko) | 2020-12-04 |
| RU2020129154A (ru) | 2022-03-10 |
| CN111902721A (zh) | 2020-11-06 |
| MX2020008345A (es) | 2020-09-25 |
| JP2024001208A (ja) | 2024-01-09 |
| WO2019154900A1 (en) | 2019-08-15 |
| US20210302440A1 (en) | 2021-09-30 |
| JP2021513077A (ja) | 2021-05-20 |
| BR112020014940A2 (pt) | 2020-12-08 |
| EP3749959A1 (en) | 2020-12-16 |
| RU2020129154A3 (cg-RX-API-DMAC7.html) | 2022-03-10 |
| US20230221339A1 (en) | 2023-07-13 |
| AU2019219071A1 (en) | 2020-07-30 |
| SG11202006686SA (en) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008345A (es) | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia. | |
| WO2017070114A3 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
| MX393482B (es) | Metodos para clasificar pacientes con un cancer solido | |
| PH12021551976A1 (en) | Cyclin-dependent kinase 2 biomarkers and uses thereof | |
| CL2018003801A1 (es) | Protector auditivo con sensores de monitoreo de posición y sonido para evitar riesgos de sonido | |
| MX2020000604A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2016001854A (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento. | |
| EP3694464A4 (en) | SYSTEMS AND PROCEDURES FOR PREVENTION, RELIEF AND / OR TREATMENT OF DEMENTIA | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| SG11202009619SA (en) | System and method for monitoring health and predicting failure of an electro-mechanical machine | |
| FR3023617B1 (fr) | Dispositif non invasif de determination de la fertilite et/ou du sexe d’un oeuf, et procede correspondant. | |
| MY207628A (en) | Biomarkers for type 2 diabetes mellitus and use thereof | |
| WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
| HK1213892A1 (zh) | Tec家族激酶抑制剂疗法的伴随诊断 | |
| WO2016057702A3 (en) | Methods for prognosing and preventing metastatic liver disease | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| PH12019501092A1 (en) | Method of eveluating corrosion | |
| MX386919B (es) | Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. | |
| MX2016009450A (es) | Ensayo novedoso para detectar periostina humana. | |
| NO20190934A1 (en) | Abnormal condition detection on PSV | |
| GB2552271A (en) | A method for diagnosing lung cancer | |
| FR3040617B1 (fr) | Equipement d'optometrie, ensemble et systeme comprenant un tel equipement |